RESUMO
Microglia are the resident immune cells of the brain, and play essential roles in neuronal development, homeostatic function, and neurodegenerative disease. Human microglia are relatively different from mouse microglia. However, most research on human microglia is performed in vitro, which does not accurately represent microglia characteristics under in vivo conditions. To elucidate the in vivo characteristics of human microglia, methods have been developed to generate and transplant induced pluripotent or embryonic stem cell-derived human microglia into neonatal or adult mouse brains. However, its widespread use remains limited by the technical difficulties of generating human microglia, as well as the need to use immune-deficient mice and conduct invasive surgeries. To address these issues, we developed a simplified method to generate induced pluripotent stem cell-derived human microglia and transplant them into the brain via a transnasal route in immunocompetent mice, in combination with a colony stimulating factor 1 receptor antagonist. We found that human microglia were able to migrate through the cribriform plate to different regions of the brain, proliferate, and become the dominant microglia in a region-specific manner by occupying the vacant niche when exogenous human cytokine is administered, for at least 60 days.
Assuntos
Células-Tronco Pluripotentes Induzidas , Doenças Neurodegenerativas , Transplante de Células-Tronco , Animais , Encéfalo/fisiologia , Diferenciação Celular/fisiologia , Humanos , Camundongos , Microglia , Nariz , Transplante de Células-Tronco/métodosRESUMO
Transient receptor potential vanilloid 4 (TRPV4) is a non-selective cation channel activated by various physical stimuli such as cell swelling and shear stress. TRPV4 is expressed in bladder sensory nerves and epithelium, and its activation produces urinary dysfunction in rodents. However, there have been few reports regarding its involvement in bladder pain. Therefore, we investigated whether TRPV4 is involved in bladder pain in mouse cystitis model. Intraperitoneal injection of cyclophosphamide (CYP; 300 mg/kg) produced mechanical hypersensitivity in the lower abdomen associated with a severe inflammatory bladder in mice. The mechanical threshold was reversed significantly in Trpv4-knockout (KO) mice. Repeated injections of CYP (150 mg/kg) daily for 4 days provoked mild bladder inflammation and persistent mechanical hypersensitivity in mice. Trpv4-KO mice prevented a reduction of the mechanical threshold without an alteration in bladder inflammation. A selective TRPV4 antagonist also reversed the mechanical threshold in chronic cystitis mice. Although expression of Trpv4 was unchanged in the bladders of chronic cystitis mice, the level of phosphorylated TRPV4 was increased significantly. These results suggest involvement of TRPV4 in bladder pain of cystitis mice. A TRPV4 antagonist might be useful for patients with irritable bladder pain such as those with interstitial cystitis/painful bladder syndrome.
Assuntos
Analgésicos/farmacologia , Cistite Intersticial/prevenção & controle , Gânglios Espinais/efeitos dos fármacos , Dor Nociceptiva/prevenção & controle , Canais de Cátion TRPV/antagonistas & inibidores , Bexiga Urinária/efeitos dos fármacos , Animais , Comportamento Animal/efeitos dos fármacos , Células Cultivadas , Ciclofosfamida , Cistite Intersticial/induzido quimicamente , Cistite Intersticial/metabolismo , Cistite Intersticial/fisiopatologia , Modelos Animais de Doenças , Gânglios Espinais/metabolismo , Gânglios Espinais/fisiopatologia , Masculino , Camundongos Endogâmicos C57BL , Camundongos Knockout , Dor Nociceptiva/induzido quimicamente , Dor Nociceptiva/metabolismo , Dor Nociceptiva/fisiopatologia , Limiar da Dor/efeitos dos fármacos , Fosforilação , Canais de Cátion TRPV/genética , Canais de Cátion TRPV/metabolismo , Bexiga Urinária/metabolismo , Bexiga Urinária/fisiopatologiaRESUMO
Naloxone is a µ-opioid receptor antagonist that has been used to prevent overdose-related respiratory depression and deaths by the illicit use of opioids. Naloxone can also deter the abuse potential of opioids, but little has been reported regarding its antagonistic activity profile against opioid-induced psychological dependence. This study aimed to confirm the antagonistic activity profile of naloxone against several µ-opioid receptor agonists and investigate whether naloxone could affect the psychological dependence induced by widely used µ-opioid receptor agonist, oxycodone. In the Guanosine-5'-o-(3-thio) triphosphate (GTPγS) binding assay, naloxone (30-30,000â¯nM) inhibited the GTPγS binding induced by oxycodone, hydrocodone, morphine, and fentanyl. It elicited parallel rightward shifts in the concentration-response curves, indicating that naloxone possessed a competitive antagonistic activity profile against these µ-opioid receptor agonists. In the conditioned place preference test, oxycodone (0.01-1â¯mg/kg, i.v.) produced dose-dependent increases in place preference. The increased place preference induced by oxycodone (1â¯mg/kg) was significantly attenuated by co-administration of naloxone at a dose of 0.5â¯mg/kg but not 0.01â¯mg/kg. Naloxone (0.5â¯mg/kg, i.v.) also blocked oxycodone (1â¯mg/kg)-induced dopamine release in nucleus accumbens; however, at a lower dose (0.01â¯mg/kg), it did not affect the intrinsic dopamine release by oxycodone. These results indicate that the psychological dependence of oxycodone could be antagonized by naloxone, depending on the dose. This characterization might lead to a better understanding of the competitive antagonistic activity profile of naloxone for µ-opioid receptor in the brain.
Assuntos
Naloxona/farmacologia , Antagonistas de Entorpecentes/farmacologia , Transtornos Relacionados ao Uso de Opioides , Analgésicos Opioides/efeitos adversos , Animais , Masculino , Oxicodona/efeitos adversos , Ratos , Ratos Sprague-Dawley , Receptores Opioides mu/agonistas , Receptores Opioides mu/efeitos dos fármacosRESUMO
Diffuse noxious inhibitory control (DNIC) is a phenomenon to reflect descending pain modulation in animals. Conditioned pain modulation (CPM) is the human counterpart of DNIC and is reduced in patients with several chronic pain conditions. Duloxetine is a serotonin and noradrenaline reuptake inhibitor that ameliorates CPM impairment in patients with diabetic neuropathy. Although some studies have reported the effects of different pharmacological agents on CPM, few studies have compared the effects of some analgesics in both humans and rodents. Therefore, we established a stable evaluation method for DNIC in rats and determined whether duloxetine and other specific analgesics affect DNIC impairment in rat models of peripheral neuropathic pain and osteoarthritis pain, two types of chronic pain. As a conditioning stimulus, capsaicin was injected into the forepaw of rats. The paw withdrawal threshold (PWT) in response to mechanical pressure was measured for the hindpaw. Peripheral neuropathic pain and osteoarthritis pain models were developed by partial sciatic nerve ligation (PSNL) and the intra-articular injection of 2â¯mg monoiodoacetate (MIA), respectively. Capsaicin (30-100⯵g/site) increased the PWT, in a dose-dependent manner, in naive rats. The threshold significantly increased at 30⯵g and reached its maximal level at 100⯵g. The change in PWT following capsaicin injection was significantly reduced in PSNL-treated rats, but the threshold was increased by the subcutaneous administration of duloxetine (10â¯mg/kg). The oral administrations of pregabalin (10â¯mg/kg) and celecoxib (3â¯mg/kg) did not affect the PWT in PSNL-treated rats. Similarly, MIA-injected rats also showed a reduced change in PWT following capsaicin injection. Duloxetine, but not pregabalin and celecoxib, significantly increased the PWT in MIA-injected rats. These results suggested that duloxetine can directly ameliorate DNIC impairment in rat models of chronic pain. Duloxetine may be useful for modulating chronic pain by restoring function to the endogenous, descending, inhibitory pathway.
Assuntos
Analgésicos/farmacologia , Dor Crônica/tratamento farmacológico , Controle Inibitório Nociceptivo Difuso/efeitos dos fármacos , Cloridrato de Duloxetina/farmacologia , Osteoartrite do Joelho/tratamento farmacológico , Animais , Controle Inibitório Nociceptivo Difuso/fisiologia , Masculino , Neuralgia/tratamento farmacológico , Neuralgia/fisiopatologia , Medição da Dor/efeitos dos fármacos , Pregabalina/farmacologia , Ratos Sprague-DawleyRESUMO
Most advanced knee osteoarthritis (OA) patients experience chronic pain resistant to cyclooxygenase (COX) inhibitors. However, the cells and molecules involved in this advanced OA pain remain poorly understood. In this study, we developed a rat model of advanced knee OA by modification of the monoiodoacetate-induced OA pain model and examined involvement of synovial macrophages in advanced OA pain. Cyclooxygenase inhibitors, such as celecoxib and naproxen, and a steroid were ineffective, but an opioid and anti-nerve growth factor (NGF) antibody was effective for pain management in the advanced OA model. Similar to advanced OA patients, histological analysis indicated severe bone marrow damages, synovitis, and cartilage damage and an increase of macrophages with high expression of interleukin-1ß, NGF, nitric oxide synthase (NOS) 1, NOS2, and COX-2 in the knee joint of the advanced OA model. Intravenous injection of clodronate liposomes depleted synovial macrophages, which decreased the level of not only proinflammatory mediator interleukin-1ß but also NGF in the knee joint, leading to pain suppression in the advanced OA model. These data suggest the involvement of synovial macrophages in advanced knee OA pain resistant to COX inhibitors by increasing proinflammatory mediators, and that drugs targeting synovial macrophages might have potent analgesic effects.
Assuntos
Celecoxib/uso terapêutico , Inibidores de Ciclo-Oxigenase 2/uso terapêutico , Macrófagos/patologia , Osteoartrite do Joelho/complicações , Dor/etiologia , Líquido Sinovial/citologia , Animais , Ciclo-Oxigenase 2/genética , Ciclo-Oxigenase 2/metabolismo , Citocinas/genética , Citocinas/metabolismo , Dinoprostona/metabolismo , Modelos Animais de Doenças , Citometria de Fluxo , Força da Mão/fisiologia , Ácido Iodoacético/toxicidade , Masculino , Fator de Crescimento Neural/genética , Fator de Crescimento Neural/metabolismo , Óxido Nítrico Sintase Tipo I/genética , Óxido Nítrico Sintase Tipo I/metabolismo , Osteoartrite do Joelho/induzido quimicamente , Medição da Dor , RNA Mensageiro , Ratos , Ratos Sprague-Dawley , Líquido Sinovial/metabolismo , Suporte de Carga/fisiologiaRESUMO
Microglia exhibit various activation phenotypes in the spinal cord after peripheral nerve injury, and promote neuropathic pain. Ibudilast is a phosphodiesterase inhibitor with anti-inflammatory activity, but its effect on activated microglia in chronic neuropathic pain is poorly understood. We investigated whether ibudilast was effective on established allodynia associated with activated microglial phenotypes in two rat models of peripheral and central neuropathic pain. A single intrathecal injection of ibudilast (25⯵g) inhibited established allodynia on days 7-21 after sciatic nerve injury in rats. Repeated injections of ibudilast (25⯵g/day) reduced the numbers of phosphorylated p38-positive cells without changing hypertrophic microglia, whereas minocycline (100⯵g/day) decreased the numbers of hypertrophic microglia associated with phosphorylated p38 levels in the spinal cord. Gene analysis revealed that minocycline, but not ibudilast, increased the expression of anti-inflammatory cytokine genes Il10 and Tgfß1 in the spinal cord. Propentofylline (100⯵g/day) was less effective on microglial phenotypes and established allodynia. Ibudilast inhibited persistent allodynia after the recovery of motor deficits in experimental autoimmune encephalomyelitis rats. Therefore, ibudilast might be effective for chronic neuropathic pain after peripheral and central nerve damage. Ibudilast mediated these effects on activated microglia using a different mechanism compared with minocycline and propentofylline.
Assuntos
Hiperalgesia/tratamento farmacológico , Microglia/efeitos dos fármacos , Neuralgia/tratamento farmacológico , Inibidores de Fosfodiesterase/farmacologia , Piridinas/farmacologia , Animais , Encefalomielite Autoimune Experimental/complicações , Encefalomielite Autoimune Experimental/etiologia , Feminino , Humanos , Hiperalgesia/etiologia , Injeções Espinhais , Masculino , Minociclina/farmacologia , Neuralgia/etiologia , Fármacos Neuroprotetores/farmacologia , Medição da Dor , Traumatismos dos Nervos Periféricos/complicações , Traumatismos dos Nervos Periféricos/etiologia , Inibidores de Fosfodiesterase/uso terapêutico , Fosforilação , Piridinas/uso terapêutico , Ratos , Ratos Endogâmicos Lew , Ratos Sprague-Dawley , Nervo Isquiático/lesões , Medula Espinal/citologia , Xantinas/farmacologia , Proteínas Quinases p38 Ativadas por Mitógeno/metabolismoRESUMO
BACKGROUND AND PURPOSE: Acid has long been thought to play an important role in the pain process. Animal study showed that repeated acid stimulation induced central sensitization. The purpose of the study is to investigate muscle pain and hyperalgesia evoked by intramuscular infusion of saline at different pH levels, and to compare the effect of a single versus repeated acid infusions. METHODS: Twenty healthy subjects received infusions of buffered saline (pH 5.0, 6.0, and 7.4) into the brachioradialis muscle in a randomized order. Twelve of the subjects received repeated infusions. The subjects rated the pain intensity on visual analogue scale (VAS). Thermal pain sensitivity, and pressure pain threshold (PPT) were assessed in both arm before, during, immediately after, one hour after, and one day after the infusion. A McGill Pain Questionnaire and pain mapping were completed after each infusion. RESULTS: The pH 5 solution caused significantly higher pain and larger areas than pH 6.0 or 7.4. The local PPTs were significantly decreased (hyperalgesia) during and immediately after infusion of all three solutions. No significant differences were detected between the first and second infusion. CONCLUSIONS: The intensity of acid-induced muscle pain is pH-dependent. All three solutions induced pressure hyperalgesia at the infusion site. Repeated infusions did not induce increased pain or prolonged hyperalgesia as compared with a single injection. Human intramuscular acidic saline infusion could not produce chronic pain model. IMPLICATIONS: The acid-induced pain model may reflect the early stage responses to tissue injury of clinical conditions. Repeated intramuscular acidic saline injection model of prolonged hyperalgesia in rodents could not be translated into a human for modelling chronic musculoskeletal pain.
Assuntos
Ácidos , Antebraço , Hiperalgesia/induzido quimicamente , Injeções Intramusculares/métodos , Mialgia , Solução Salina/administração & dosagem , Feminino , Humanos , Masculino , Medição da Dor/métodos , Limiar da Dor , Fatores Sexuais , Adulto JovemRESUMO
A novel series of (6-aminopyridin-3-yl)(4-(pyridin-2-yl)piperazin-1-yl) methanone derivatives were identified as selective transient receptor potential vanilloid 4 (TRPV4) channel antagonist and showed analgesic effect in Freund's Complete Adjuvant (FCA) induced mechanical hyperalgesia model in guinea pig and rat. Modification of right part based on the compound 16d which was disclosed in our previous communication led to the identification of compound 26i as a flagship compound. In this paper, we described the details about design, synthesis and structure-activity relationship (SAR) analysis at right and left part of these derivatives (Fig. 1).
Assuntos
Analgésicos/farmacologia , Compostos Azabicíclicos/farmacologia , Manejo da Dor/métodos , Canais de Cátion TRPV/antagonistas & inibidores , Tiazóis/farmacologia , Analgésicos/química , Animais , Compostos Azabicíclicos/química , Cobaias , Humanos , Microssomos/efeitos dos fármacos , Espectroscopia de Prótons por Ressonância Magnética , Ratos , Espectrometria de Massas por Ionização por Electrospray , Relação Estrutura-Atividade , Tiazóis/químicaRESUMO
Because of the incomplete understanding of the molecular mechanisms that underlie chronic pain, the currently available treatments for this type of pain remain inefficient. In this study, we show that Netrin-4, a member of the axon guidance molecule family, was expressed in dorsal horn inner lamina II excitatory interneurons in the rat spinal cord. A similar expression pattern for Netrin-4 was also observed in human spinal cord. Behavioral analysis revealed that tactile and heat hyperalgesia after peripheral nerve injury or inflammation were abolished in Netrin-4-mutant rats. Transient suppression of Netrin-4 or its receptor Unc5B after injury could also prevent allodynia. Conversely, intrathecal administration of Netrin-4 protein to naive rats enhanced excitatory synaptic transmission in the dorsal horn and induced allodynia, suggesting that Netrin-4 is involved in spinal sensitization. Furthermore, the Unc5B receptor and subsequent activation of the tyrosine phosphatase SHP2 mediated Netrin-4-induced pain signaling in the spinal cord. These results identify Netrin-4 as a novel protein regulating spinal sensitization leading to chronic pain. Our findings provide evidence for the function of Netrin in the adult nervous system, as well as a previously unknown function in inducing pain signals from dorsal horn interneurons.
Assuntos
Dor Crônica/metabolismo , Fatores de Crescimento Neural/metabolismo , Receptores de Superfície Celular/metabolismo , Transdução de Sinais , Corno Dorsal da Medula Espinal/metabolismo , Traumatismos da Medula Espinal/metabolismo , Animais , Dor Crônica/genética , Dor Crônica/patologia , Ativação Enzimática/genética , Feminino , Fatores de Crescimento Neural/genética , Proteína Tirosina Fosfatase não Receptora Tipo 11/genética , Proteína Tirosina Fosfatase não Receptora Tipo 11/metabolismo , Ratos , Ratos Mutantes , Ratos Wistar , Receptores de Superfície Celular/genética , Corno Dorsal da Medula Espinal/patologia , Traumatismos da Medula Espinal/genética , Traumatismos da Medula Espinal/patologiaRESUMO
A series of 2',4'-dimethyl-[4,5'-bithiazol]-2-yl amino derivatives have been identified as selective TRPV4 antagonists that display inhibition potencies against 4α-phorbol 12,13-didecanoate (4αPDD), well known as a TRPV4 selective agonist and/or a hypotonicity. In particular, 9-(6-((2',4'-dimethyl-[4,5'-bithiazol]-2-yl)amino)nicotinoyl)-3-oxa-9-azabicyclo[3.3.1]nonan-7-one showed an analgesic effect in Freund's Complete Adjuvant (FCA) induced mechanical hyperalgesia model in guinea pig (reported in Part 1). However, there are some concerns such as species differences and the need for higher plasma exposure to achieve target efficacy for evaluation by an in vivo pain model. In this Letter, we report the resolution of some of the problems by further optimizing the chemical scaffold.
Assuntos
Canais de Cátion TRPV/antagonistas & inibidores , Tiazóis/farmacologia , Administração Oral , Animais , Disponibilidade Biológica , Cricetinae , Descoberta de Drogas , Relação Estrutura-Atividade , Tiazóis/administração & dosagem , Tiazóis/química , Tiazóis/farmacocinéticaRESUMO
Dysfunction in the central serotonin (5-HT) and norepinephrine (NE) systems cause depression and pain. Descending spinal pain modulatory pathways are important in the analgesic mechanisms of antidepressants, particularly serotonin and norepinephrine reuptake inhibitors (SNRIs). While many non-clinical studies have demonstrated the roles of central monoaminergic systems in pain, there is little evidence to illuminate the direct contribution of spinal descending pain modulatory systems independently of depressive-like behavior. To examine the effects of dysfunction of spinal monoaminergic systems on pain sensitivity, we established a rat chronic pain model by administering lumbar-intrathecal reserpine to minimize its influence on brain. Lumbar-intrathecal reserpine evoked persistent mechanical hypersensitivity and corresponding reductions in spinal 5-HT and NE concentrations (from 767.2 to 241.6ng/g and from 455.9 to 41.7ng/g, respectively after reserpine 30nmol). Lumbar-intrathecal reserpine did not deplete brain monoamines or bring about depressive-like behavior in the forced swim test. Spinal monoamines depletion-induced pain sensitivity was ameliorated by lumbar-intrathecal administration of the SNRIs (duloxetine and milnacipran) in dose-dependent manners. These suggest that increased pain sensitivity could be induced by dysfunction solely of the descending pain modulatory system, regardless of depressive-like behavior, and lumbar-intrathecal administration of SNRIs could ameliorate the pain sensitivity which might be mediated by affecting the descending pain modulatory system in the spinal cord, not via their antidepressant effects.
Assuntos
Analgésicos/farmacologia , Monoaminas Biogênicas/metabolismo , Dor Crônica/tratamento farmacológico , Neurônios/metabolismo , Inibidores da Recaptação de Serotonina e Norepinefrina/farmacologia , Medula Espinal/metabolismo , Administração Cutânea , Analgésicos/administração & dosagem , Animais , Encéfalo/metabolismo , Dor Crônica/metabolismo , Dor Crônica/fisiopatologia , Ciclopropanos/administração & dosagem , Ciclopropanos/farmacologia , Cloridrato de Duloxetina/administração & dosagem , Cloridrato de Duloxetina/farmacologia , Injeções Espinhais , Milnaciprano , Norepinefrina/metabolismo , Limiar da Dor , Ratos Sprague-Dawley , Reserpina/administração & dosagem , Reserpina/farmacologia , Serotonina/metabolismo , Inibidores da Recaptação de Serotonina e Norepinefrina/uso terapêutico , Medula Espinal/efeitos dos fármacos , Proteínas Vesiculares de Transporte de Monoamina/antagonistas & inibidoresRESUMO
A series of novel tetrahydropyridinecarboxamide TRPV1 antagonists were prepared and evaluated in an effort to optimize properties of previously described lead compounds from piperazinecarboxamide series. The compounds were evaluated for their ability to block capsaicin and acid-induced calcium influx in CHO cells expressing human TRPV1. The most potent of these TRPV1 antagonists were further characterized in pharmacokinetic, efficacy, and body temperature studies. On the basis of its pharmacokinetic, in vivo efficacy, safety, and toxicological properties, compound 37 was selected for further evaluation in human clinical trials.
Assuntos
Aminopiridinas/química , Analgésicos/química , Dor/tratamento farmacológico , Canais de Cátion TRPV/antagonistas & inibidores , Aminopiridinas/farmacocinética , Aminopiridinas/farmacologia , Analgésicos/farmacocinética , Analgésicos/farmacologia , Animais , Temperatura Corporal/efeitos dos fármacos , Células CHO , Cálcio/metabolismo , Capsaicina/farmacologia , Cricetulus , Adjuvante de Freund , Gânglios Espinais/citologia , Humanos , Concentração de Íons de Hidrogênio , Masculino , Dor/etiologia , Ratos Sprague-Dawley , Células Receptoras Sensoriais/efeitos dos fármacos , Células Receptoras Sensoriais/fisiologia , Estereoisomerismo , Relação Estrutura-AtividadeRESUMO
Adult mice abundantly express neudesin, an extracellular heme-binding protein with neurotrophic activity, in white adipose tissues. At the early stage of adipocyte differentiation during adipogenesis, however, the expression of neudesin decreased transiently. Neudesin-hemin significantly suppressed adipogenesis in 3T3-L1 cells. The knockdown of neudesin by RNA interference markedly promoted adipogenesis in 3T3-L1 cells and decreased MAPK activation during adipocyte differentiation. The addition or knockdown of neudesin affected the expression of C/EBPalpha and PPARgamma but not of C/EBPbeta. These findings suggest that neudesin plays a critical role in the early stage of adipocyte differentiation in which C/EBPbeta induces PPARgamma and C/EBPalpha expressions, by controlling the MAPK pathway.
Assuntos
Adipócitos/fisiologia , Adipogenia , Sistema de Sinalização das MAP Quinases , Proteínas do Tecido Nervoso/fisiologia , Células 3T3-L1 , Adipócitos/enzimologia , Animais , Proliferação de Células , Técnicas de Silenciamento de Genes , Camundongos , Proteínas do Tecido Nervoso/genética , Interferência de RNARESUMO
Orexin is one of the orexigenic neuropeptides in the hypothalamus. Orexin neurons in the lateral hypothalamus (LH) project into the cerebral cortex and hippocampus in which the receptors are distributed in high concentrations. Therefore, to elucidate the actions of orexin in the cerebral cortex, we examined its effects on the mRNA expressions of N-methyl-d-aspartate (NMDA) receptor subunits (NR1, NR2A, NR2B) and alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate (AMPA) receptor subunits (GluR1, GluR2) following 6-day application of orexin-A or orexin-B to rat primary cortical neuron cultures. The mRNAs of NR1 and NR2A subunits were significantly decreased by orexin-A and orexin-B at concentrations over 0.1 microM and 0.01 microM, respectively. The mRNA expression of NR2B subunit was also significantly decreased by orexin-A and orexin-B only at the concentration of 1 microM. Moreover, orexin-A and orexin-B at concentrations over 0.01 microM significantly decreased the mRNA expressions of AMPA receptor subunits, GluR1 and GluR2. The present study demonstrated that orexins significantly suppressed RNA expressions of NMDA and AMPA receptor subunits in cortical neuron cultures, suggesting that orexin may regulate the higher functions of the cerebral cortex as well as be involved in energy regulation in the hypothalamus.
Assuntos
Peptídeos e Proteínas de Sinalização Intracelular/fisiologia , Neurônios/metabolismo , Neuropeptídeos/fisiologia , RNA Mensageiro/metabolismo , Receptores de AMPA/biossíntese , Receptores de N-Metil-D-Aspartato/biossíntese , Animais , Hipotálamo/metabolismo , Neurônios/efeitos dos fármacos , Orexinas , Subunidades Proteicas/biossíntese , RatosRESUMO
Rat brain endothelial cell derived gene-1 (BEC-1) had considerable homology with tumor suppressor candidate 5 (TUSC5). TUSC5 was expressed abundantly, and its mRNA was inhibited by cold exposure in rat brown adipose tissue (BAT). In the present study, we investigated its regulatory mechanism using primary cultured rat brown preadipocytes (RBPA) and Zucker lean rats (ZL). We found that: (1) TUSC5 mRNA began to increase in a manner similar to C/EBP-alpha, PPAR-gamma, and adiponectin during differentiation in RBPA; (2) neither beta3-adrenoceptor agonist BRL 37344 nor dexamethasone affected TUSC5 mRNA in RBPA; (3) propranolol did not block the decrease of TUSC5 mRNA by cold exposure in ZL; (4) BRL 37344 did not influence TUSC5 mRNA in ZL; and (5) dexamethasone inhibited TUSC5 mRNA in a dose-dependent manner similar to UCP-1 in ZL. These data suggested that TUSC5 is involved in the differentiation, and its expression is regulated independently of the beta-adrenergic pathway in BAT.
Assuntos
Adipócitos Marrons/citologia , Adipócitos Marrons/metabolismo , Canais Iônicos/metabolismo , Proteínas Mitocondriais/metabolismo , Células-Tronco/citologia , Células-Tronco/metabolismo , Proteínas Supressoras de Tumor/metabolismo , Animais , Diferenciação Celular , Proliferação de Células , Células Cultivadas , Regulação da Expressão Gênica/fisiologia , Ratos , Ratos Zucker , Proteína Desacopladora 1RESUMO
The development of white adipose tissue (WAT) involves adipogenesis and cell proliferation. Although the adipogenesis has been well studied, the cell proliferation has not. Therefore, we examined the mechanism of the proliferation by analyzing Fgf10(-/-) mouse embryonic WAT, in which adipogenesis and proliferation were severely impaired. D-type cyclin expression and retinoblastoma family protein phosphorylation essential for cell proliferation were examined in WAT. Both cyclin D2 expression and p130 phosphorylation were impaired in the Fgf10(-/-) WAT. In mouse embryonic fibroblasts, Fgf10 stimulated cyclin D2 expression and p130 phosphorylation, which were inhibited by an inhibitor of the Ras/MAPK pathway. These results suggest that Fgf10 stimulates cell proliferation in WAT through the Ras/MAPK pathway followed by the cyclin D2-dependent phosphorylation of p130. In contrast, expression but not phosphorylation of pRb was impaired in the Fgf10(-/-) WAT. As pRb is essential for adipogenesis, Fgf10 might play a role in adipogenesis by inducing its expression.
Assuntos
Tecido Adiposo/citologia , Fator 10 de Crescimento de Fibroblastos/fisiologia , Adipogenia/fisiologia , Tecido Adiposo/metabolismo , Animais , Proliferação de Células , Ciclina D2 , Ciclinas/metabolismo , Embrião de Mamíferos/citologia , Embrião de Mamíferos/metabolismo , Fibroblastos/citologia , Fibroblastos/metabolismo , Sistema de Sinalização das MAP Quinases/fisiologia , Camundongos , Fosforilação , Proteína do Retinoblastoma/metabolismo , Proteína p130 Retinoblastoma-Like/metabolismoRESUMO
The development of white adipose tissue (WAT) of Fgf10-/- mouse embryos was greatly impaired. Here, we examined the mechanism of Fgf10 action in adipogenesis in vivo. The proliferative activity in the WAT of Fgf10-/- embryos was greatly decreased. We also examined the expression of transcription factors, C/EBPbeta, C/EBPalpha and PPARgamma, that are important for adipogenesis. Although the expression of C/EBPbeta and PPARgamma in the WAT of Fgf10-/- embryos was greatly decreased, the expression of C/EBPalpha was essentially unchanged. Therefore, we examined their expression in the WAT of C/EBPalpha-/- embryos. Although the expression of C/EBPbeta and PPARgamma in the WAT was greatly decreased, the expression of Fgf10 was essentially unchanged. As these results in vivo appeared to be contradictory to a transcriptional cascade model in vitro that C/EBPbeta induces the expression of PPARgamma and C/EBPalpha reported, we also examined their expression in the WAT of wild type embryos at different developmental stages. The expression of Fgf10 and C/EBPalpha was followed by that of C/EBPbeta and PPARgamma. The present findings indicate that Fgf10 but not C/EBPalpha is required for the proliferation of preadipocytes. In contrast, both Fgf10 and C/EBPalpha acting synergistically in separate, parallel pathways are required for the differentiation. Unexpectedly, the transcriptional cascade of adipogenesis in vivo described here is distinct from the cascade in vitro previously reported.
Assuntos
Tecido Adiposo/crescimento & desenvolvimento , Fatores de Crescimento de Fibroblastos/metabolismo , Adipócitos/fisiologia , Tecido Adiposo/citologia , Tecido Adiposo/fisiologia , Animais , Proteína alfa Estimuladora de Ligação a CCAAT/genética , Proteína alfa Estimuladora de Ligação a CCAAT/metabolismo , Proteína beta Intensificadora de Ligação a CCAAT/genética , Proteína beta Intensificadora de Ligação a CCAAT/metabolismo , Diferenciação Celular/fisiologia , Células Cultivadas , Embrião de Mamíferos/anatomia & histologia , Embrião de Mamíferos/fisiologia , Fator 10 de Crescimento de Fibroblastos , Fatores de Crescimento de Fibroblastos/genética , Fibroblastos/citologia , Fibroblastos/metabolismo , Camundongos , Camundongos Endogâmicos C57BL , Camundongos Knockout , Proteínas Quinases Ativadas por Mitógeno/metabolismo , Morfogênese/fisiologia , Receptores Citoplasmáticos e Nucleares/genética , Receptores Citoplasmáticos e Nucleares/metabolismo , Fatores de Transcrição/genética , Fatores de Transcrição/metabolismo , Transcrição GênicaRESUMO
Fibroblast growth factors (FGFs) are important intercellular signaling molecules in developmental processes. Here, we show that FGF10 is secreted by cultured preadipocytes and that prevention of FGF10 signaling inhibits the expression of C/EBPbeta and the subsequent differentiation of these cells. An active form of C/EBPbeta rescued differentiation of the cells in which FGF10 signaling was blocked. Development of white adipose tissue and the expression of C/EBPbeta in this tissue of FGF10 knockout mice were markedly reduced, and the ability of embryonic fibroblasts derived from FGF10 knockout mice to differentiate into adipocytes was impaired. Therefore, FGF10 plays an important role in adipogenesis, at least partly by contributing to the expression of C/EBPbeta through an autocrine/paracrine mechanism.